Jaimie Shing

Dr. Jaimie Shing

Vanderbilt University Medical Center
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ESErica S. Stephens
Erica S. Stephens
EDEmily Dema
Emily Dema
JMJennifer K. McGee-Avila
Jennifer K. McGee-Avila
MSMeredith S. Shiels
Meredith S. Shiels
AKAimée R. Kreimer
Aimée R. Kreimer
JSJaimie Shing
Jaimie Shing
Human papillomavirus (HPV) is the most common sexually transmitted infection in the US.1 Persistent high-risk HPV type infections can lead to the development of cancer at multiple anatomical sites, including the cervix, anus, vulva, vagina, penis, and oropharynx.2 Human papillomavirus vaccines protect against several carcinogenic HPV genotypes and constitute a well-researched, evidence-based primary prevention strategy that has the potential to reduce many HPV-driven cancers.

13 June 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJaimie Shing
Jaimie Shing
SHShangying Hu
Shangying Hu
RHRolando Herrero
Rolando Herrero
AHAllan Hildesheim
Allan Hildesheim
CPCarolina Porras
Carolina Porras
MSMark H. Stoler
Mark H. Stoler

10 June 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJaimie Shing
Jaimie Shing
KLKathleen N Ly
Kathleen N Ly
JXJian Xing
Jian Xing
ETEyasu H Teshale
Eyasu H Teshale
RJRuth B Jiles
Ruth B Jiles
Background: Hepatitis B virus (HBV) can transmit through needle sharing. The national HBV infection prevalence in persons who inject drugs remains ill-defined. We estimated the prevalence of total HBV core antibody (anti-HBc) positivity, indicating a previous or ongoing HBV infection, among adults aged 20–59 years with an injection drug use (IDU) history. We compared select characteristics by anti-HBc status. Methods: Using 2001–2016 National Health and Nutrition Examination Survey data, we calculated the anti-HBc positivity prevalence among adults with IDU histories and among the general US population. For adults with IDU histories, we compared sex, age group, birth cohort, race/ethnicity, health insurance coverage, and hepatitis A immunity by anti-HBc status. Using marginal structural models, we calculated model-adjusted prevalence rates and ratios to determine the characteristics associated with anti-HBc positivity among adults with IDU histories. Results: From 2001–2016, the anti-HBc positivity prevalence was 19.7% (95% confidence interval [CI] 16.0–24.0%) among those with IDU histories, compared with 4.6% (95% CI 4.3–5.0%) in the general population. The HBV surface antigen positivity prevalence was 0.4% (95% CI 0.3–0.5%) in the general population. Among adults with IDU histories, 19.8% reported prior-year IDU and 28.5% had a hepatitis A immunity. Conclusions: One-fifth of adults with IDU histories had a previous or ongoing HBV infection: a rate over 4 times higher than the prevalence in the general population. One-fifth of adults with IDU histories reported prior-year use. Programs promoting safe IDU practices, drug treatment, and hepatitis A and B vaccinations should be key components of viral hepatitis prevention.

15 February 2023 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
JSJaimie Shing
Jaimie Shing
JCJereme Corbin
Jereme Corbin
AKAimée R Kreimer
Aimée R Kreimer
LCLoretto J Carvajal
Loretto J Carvajal
KTKekoa Taparra
Kekoa Taparra
JVJacqueline B Vo
Jacqueline B Vo
Background: Asian Americans and Native Hawaiians and other Pacific Islanders have suboptimal human papillomavirus (HPV) vaccination and cancer screening rates. Asian Americans and NHPIs are often aggregated, masking disparities characterized by varying colonization and immigration patterns and cultural and religious beliefs between populations and ethnicities. We examined the incidence of HPV-associated cancers across disaggregated Asian American and NHPI ethnicities.Methods: Using the Surveillance, Epidemiology, and End Results Detailed Asian/Pacific Islander database, we calculated 1990 to 2014 sex-specific, age-standardized HPV-associated cancer incidence of cervical carcinoma, oropharyngeal squamous cell carcinoma (SCC), vulvar SCC, vaginal SCC, anal SCC, and penile SCC by ethnicity: Asian Indian and Pakistani, Chinese, Filipino, Japanese, Kampuchean, Korean, Laotian, Native Hawaiian, other Pacific Islander, and Vietnamese. Trends by calendar period (1990 to 1996, 1997 to 2002, 2003 to 2008, 2009 to 2014) were estimated using Joinpoint regression.Results: The most common HPV-associated cancer was cervical carcinoma in women and oropharyngeal SCC in men. During 1990 to 2014, cervical carcinoma incidence per 100 000 ranged from 4.5 (Asian Indian and Pakistani) to 20.7 (Laotian). Cervical carcinoma incidence only statistically significantly declined for Asian Indian and Pakistani, Filipino, Korean, Laotian, and Vietnamese women (range = 19.9% to 44.1% decline per period). Among men, oropharyngeal SCC incidence per 100 000 ranged from 1.1 (Chinese) to 5.1 (Native Hawaiian). Oropharyngeal SCC incidence only statistically significantly increased (31.0% increase per period) for Japanese men. Heterogeneity across ethnicities were observed for other cancer sites.Conclusions: HPV-associated cancer incidence varied widely between Asian Americans and NHPIs and by ethnicity, underscoring the need for improved data capture of ethnic groups in research and more tailored interventions to better address health disparities between Asian American and NHPI populations.

30 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KTKekoa Taparra
Kekoa Taparra
BIBrandon I. Ing
Brandon I. Ing
AEAgnes Ewongwo
Agnes Ewongwo
JVJacqueline B. Vo
Jacqueline B. Vo
JSJaimie Shing
Jaimie Shing
EKElizabeth Kidd
Elizabeth Kidd
Brachytherapy improves clinical outcomes among women diagnosed with cervical and endometrial cancers. Recent evidence demonstrates that declining brachytherapy boosts for women with cervical cancer were associated with higher mortality. In this retrospective cohort study, women diagnosed with endometrial or cervical cancer in the United States between 2004 and 2017 were selected from the National Cancer Database for evaluation. Women ≥18 years of age were included for high intermediate risk (PORTEC-2 and GOG-99 definition) or FIGO Stage II-IVA endometrial cancers and FIGO Stage IA-IVA—non-surgically treated cervical cancers. The aims were to (1) evaluate brachytherapy treatment practice patterns for cervical and endometrial cancers in the United States; (2) calculate rates of brachytherapy treatment by race; and (3) determine factors associated with not receiving brachytherapy. Treatment practice patterns were evaluated over time and by race. Multivariable logistic regression assessed predictors of brachytherapy. The data show increasing rates of brachytherapy for endometrial cancers. Compared to non-Hispanic White women; Native Hawaiian and other Pacific Islander (NHPI) women with endometrial cancer and Black women with cervical cancer were significantly less likely to receive brachytherapy. For both NHPI and Black women, treatment at community cancer centers was associated with a decreased likelihood of brachytherapy. The data suggest racial disparities among Black women with cervical cancer and NHPI women with endometrial cancer and emphasize an unmet need for brachytherapy access within community hospitals.

8 December 2023 in The Lancet HIV
Verified
Journal Article
Closed access
JSJaimie Shing
Jaimie Shing
EEEric A Engels
Eric A Engels
AAApril A Austin
April A Austin
MCMegan A Clarke
Megan A Clarke
JHJennifer H Hayes
Jennifer H Hayes
MSMeredith S Shiels
Meredith S Shiels